Roche (ROG: SIX) company Genentech has won US approval for its intravenous Actemra (tocilizumab) product, for adults that have been hospitalized with COVID-19.
Full approval for the blockbuster antibody, which was originally developed for autoimmune conditions such as rheumatoid arthritis, comes after an Emergency Use Authorization (EUA) was granted by the Food and Drug Administration (FDA) in June 2021.
While full approval for children has not been granted at this time, the EUA for this age group currently remains in place.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze